Indeed, microRNA-mediated modulation of BCL-2 family proteins proved to be an effective anti-cancer strategy in combinatorial therapies in pre-clinical models, resulting in cancer sensitization to chemotherapy. This evidence concerns the gene BCL2 and cancer.